Loading...
OTCMSZLSF
Market cap120kUSD
Dec 23, Last price  
0.00USD
1D
-94.32%
1Q
-98.28%
Name

StageZero Life Sciences Ltd

Chart & Performance

D1W1MN
OTCM:SZLSF chart
P/E
P/S
0.03
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
52.44%
Rev. gr., 5y
55.93%
Revenues
4m
-25.12%
2,905,0091,852,3694,596,5882,816,8052,188,9441,168,3561,094,301193,47998,732281,558124,0762,112,657325,8061,054,121411,669185,874138,7044,151,8105,068,1563,795,076
Net income
-15m
L+91.46%
000000000000-6,016,745-5,911,044-2,947,382-3,943,920-4,312,288-7,184,365-7,684,226-14,712,481
CFO
-4m
L-60.59%
000000000000-1,725,769-3,682,844-3,823,422-3,290,957-4,590,869-3,064,419-8,954,863-3,528,756
Earnings
May 19, 2025

Profile

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
IPO date
Oct 30, 1998
Employees
40
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,795
-25.12%
5,068
22.07%
Cost of revenue
11,203
12,888
Unusual Expense (Income)
NOPBT
(7,408)
(7,819)
NOPBT Margin
Operating Taxes
3,297
200
Tax Rate
NOPAT
(10,705)
(8,020)
Net income
(14,712)
91.46%
(7,684)
6.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,543
3,107
BB yield
-25.86%
-14.65%
Debt
Debt current
1,224
580
Long-term debt
770
1,192
Deferred revenue
Other long-term liabilities
601
2,363
Net debt
1,978
47
Cash flow
Cash from operating activities
(3,529)
(8,955)
CAPEX
(148)
Cash from investing activities
(21)
Cash from financing activities
1,833
4,103
FCF
(6,511)
(5,852)
Balance
Cash
16
1,725
Long term investments
Excess cash
1,471
Stockholders' equity
(20,412)
(9,798)
Invested Capital
15,311
16,279
ROIC
ROCE
145.20%
EV
Common stock shares outstanding
99,426
70,716
Price
0.06
-80.00%
0.30
-60.00%
Market cap
5,966
-71.88%
21,215
-36.89%
EV
7,944
21,262
EBITDA
(6,970)
(7,310)
EV/EBITDA
Interest
219
200
Interest/NOPBT